Roche’s Rituximab Gains Two New Indications In The EU
MabThera, marketed by Genentech/Biogen Idec in the U.S. as Rituxan, is now approved in Europe for maintenance NHL and RA.
MabThera, marketed by Genentech/Biogen Idec in the U.S. as Rituxan, is now approved in Europe for maintenance NHL and RA.